Boehringer Ingelheim’s Oncology Portfolio Shows Strong Promise Across Multiple Cancers at ASCO 2026

At the 2026 ASCO Annual Meeting, Boehringer Ingelheim presented new data from across its oncology clinical development program, including patient-reported outcomes (PROs) for HERNEXEOS® (zongertinib tablets) in HER2 (ERBB2)-mutant advanced NSCLC, early results in other HER2-driven cancers, and updated efficacy data for obrixtamig in extensive-stage small cell lung cancer (ES-SCLC) and extrapulmonary neuroendocrine carcinoma (epNEC).

HERNEXEOS® (Zongertinib) — PROs in HER2-Mutant NSCLC

• N=71 from Phase Ib Beamion LUNG-1. Improvements in physical functioning and NSCLC-related symptoms from baseline, sustained over time (EORTC QLQ-C30 and NSCLC-SAQ).
• Low overall side effect burden; patient-reported AEs consistent with published safety data.

HERNEXEOS® in Other HER2-Driven Cancers

• mCRC (N=19 pooled): Confirmed ORR 42%, disease control rate 95%. No grade 4/5 AEs.
• HER2-positive mGEAC (N=16): HERNEXEOS + T-DXd yielded 10 confirmed responses (1 CR, 9 PR). No grade 4/5 AEs.
• HER2-positive mBC: Cohort A (T-DM1): 3 PR, 9 SD. Cohort B (T-DXd): 4 PR, 11 SD. No new safety signals.

Obrixtamig (DLL3/CD3 T-cell Engager) — ES-SCLC

• Phase I DAREON®-8 (N=44): Confirmed ORR 73% (7% CR, 66% PR); disease control rate 91%.
• Median DoR and PFS not yet reached; 6- and 9-month PFS rates 78% and 62% respectively.
• CRS most common obrixtamig-related AE (57%). Discontinuations infrequent (n=1).

View the Boehringer Ingelheim ASCO 2026 Presentation Schedule HERE.